This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, March 7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the following two investor conferences in March:
24 th Annual Roth Conference in Dana Point on March 14, 2012 at 12:30 p.m. ET/ 9:30 a.m. PT. Kurt Gustafson, Chief Financial Officer of Halozyme Therapeutics, will provide a corporate overview.
Barclays Capital 2012 Global Healthcare Conference in Miami on March 14, 2012 at 4:15 p.m. ET/ 1:15 p.m. PT. Gregory I. Frost, Ph.D., President and Chief Executive Officer of Halozyme Therapeutics, will provide a corporate overview.
The presentations will be webcast through the "Investors" section of Halozyme's corporate website at
www.halozyme.com, and recordings will be made available for 90 days following the events. To access the live webcasts, please log on to Halozyme's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.
About Halozyme Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche,
Baxter, ViroPharma and Intrexon. Halozyme is headquartered in
San Diego, CA. For more information on how we are innovating, please visit our corporate website at
Media/Investor Contact:Anne EricksonExecutive DirectorHalozyme Therapeutics858-704-8264
SOURCE Halozyme Therapeutics, Inc.